IMAGINE MAGIC Study

Summary

The goal of this study is to create a large cohort of 8000 participants with irritable bowel syndrome, inflammatory bowel disease (Crohn's disease, ulcerative colitis), and healthy controls. Currently, we are looking to recruit children who are 4 years of age or older and/or their parents/guardians to join our study.

We will collect participant information using validated questionnaires, stool, urine and (optional) blood samples, to correlate their GI and psychological symptoms with their diet, microbiome and its metabolome.

We hope to better understand the key mechanisms in the diet-microbiome-host relationship. This will allow to use better targeted treatment of inflammatory bowel disease and irritable bowel syndrome and the psychiatric disorders associated with these diseases.

If you are interested to participate, please follow the link under "Additional Information" to express your interest, or contact the IMAGINE study team to find out more at (403) 220-4219 or imagine.magic@ucalgary.ca.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 4 to 100

Accepts healthy participants: Yes

Inclusion criteria:

1) Crohn's disease patients who are 4 years of age or older.
2) Ulcerative colitis patients who are 4 years of age or older.
3) Irritable bowel syndrome patients who are 13 years of age or older.
4) Healthy persons who are 4 years of age or older with no diagnosed gastrointestinal condition

Exclusion criteria:

Anyone who
1) does not want to participate in the study,
2) is not able to consent,
3) is unable to communicate in English,
4) is schizophrenic,
5) has an eating disorder,
6) has had major gastrointestinal surgery,
7) has any major chronic condition (e.g. liver, lung, cardiac disease; HIV),
8) has or currently suffers with colorectal cancer,
9) has microscopic colitis.

Participate

Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

IMAGINE MAGIC Team

Principal investigator:

Michelle Buresi

Clinical trial:

No

REB-ID:

REB17-1805